The main goal of high grade glioma (HGG) surgery is to achieve gross total resection (GTR) without causing new neurological deficits1-8. Intraoperative navigated high resolution ultrasound (US) is a promising new tool to acquire real-time intraoperative images to localize and to resect gliomas9-12. The aim of this study was to investigate whether intraoperative guided surgery leads to a higher rate of GTR, when compared with standard non-ultrasound guided surgery.
Study design: The US-GLIOMA study is a randomized controlled trial with blinded primary outcome measure. Study population: Fifty patients with newly diagnosed contrast enhancing presumed high grade glioma on first MRI scan. Intervention: The study consists of two treatment arms: non-ultrasound guided glioma resection (conventional treatment) versus ultrasound guided glioma resection (intervention) . Main study parameters/endpoints: * Gross total resection (yes/no) * Extent of resection (%) * Neurological outcome (Karnofsky Performance Status) * Quality of Life (EORTC QLQ-C30 and QLQ-BN20 quality of life questionnaire) * Surgery associated neurological deficits (National Institutes of Health Stroke Scale) * Adverse events (classified according to the US National Cancer Institute common toxicity criteria version 4.0) * Survival time (days)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
50
during surgery, the neurosurgeon will acquire ultrasound guided images (fused with the standard neuronavigation system) to evaluate the progress of tumor resection.
Erasmus MC
Rotterdam, South Holland, Netherlands
Gross total resection (Yes or No)
Gross-total resection (yes vs. no): No residual contrast enhancement on post-operative MRI scans; 100% of all contrast enhancing tumor has been resected when compared to initial enhancing tumor on pre-operative MRI scans.
Time frame: within 48 hours after surgery
Extent of resection (%)
as a continous variable The extent of resection (%) is a secondary outcome measurement defined as the residual tumor volumes on post-operative MRI studies compared to the operative tumor volume.
Time frame: within 48 hours after surgery
Neurological outcome (Karnofsky Performance status)
Karnofsky Performance status
Time frame: within 1 week after surgery
Quality of Life (QLQ C30 questionnaires)
QLQ C30 questionnaires A brain tumor specific quality of life measurement tool
Time frame: 1, 3 and 6 months after surgery
Quality of Life (QLQ BN20 questionnaires)
QLQ BN20 questionnaires A brain tumor specific quality of life measurement tool
Time frame: 1, 3 and 6 months after surgery
Surgery associated neurological deficits (National Institutes of Health Stroke Scale)
National Institutes of Health Stroke Scale 0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke NIHSS is a tool used by healthcare providers to objectively quantify the impairment caused typically by a stroke, however it is also used for tumor studies to assess functioning on the level of speech, motor and sensory functions.
Time frame: 1 month after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Survival (time in days)
time measured from surgery until death in days. This study has a follow up of 6 months. However, when patients are alive at months after surgery, we will contact the general practictioner of the patient 15 months after the trial to obtain survival data.
Time frame: status will be checked 15 months after surgery